MedTrace Logo

BOTOX® in the Treatment of Crow's Feet Lines in China

NCT02195687 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 417

Last updated 2016-03-14

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared with placebo in patients with moderate to severe crow's feet lines (lateral canthal lines).

Conditions

  • Lateral Canthal Lines
  • Crow's Feet Lines

Interventions

BIOLOGICAL

botulinum toxin Type A

botulinum toxin Type A (BOTOX®) injected into bilateral crow's feet line areas.

DRUG

Normal Saline

Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-02-28
Completion
2015-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02195687 on ClinicalTrials.gov